Diencephalic astrocytomas

Summary

Diencephalic astrocytomas (MONDO:0003169) is a disease. A subtype of diencephalic cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	diencephalic astrocytomas
Mondo ID	MONDO:0003169
DOID	DOID:4855
NCIT	C5128
UMLS	C1333284
MedGen	272542
GARD	0023393
Anatomy (UBERON)	UBERON:0001894
Is cancer (heuristic)	no

Also known as: astrocytoma (excluding glioblastoma) of diencephalon · astrocytoma of diencephalon · astrocytoma of the diencephalon · diencephalic astrocytoma · diencephalon astrocytoma · diencephalon astrocytoma (excluding glioblastoma)

Disease family

This is a subtype of diencephalic cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › nervous system cancer › central nervous system cancer › brain cancer › supratentorial cancer › diencephalic cancer › diencephalic astrocytomas

Related subtypes (2): thalamic cancer, chordoid glioma of the third ventricle

Subtypes (3): pineal gland astrocytoma, pituicytoma, optic tract astrocytoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.